We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$18.6M
Cap. Flow
+$5.56M
Cap. Flow %
1.53%
Top 10 Hldgs %
25.94%
Holding
173
New
49
Increased
12
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$20.1M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.18M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.64M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.41M
5
QDEL icon
QuidelOrtho
QDEL
+$5.15M

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$7.59M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.09M
3
CDNA icon
CareDx
CDNA
+$5.7M
4
HAE icon
Haemonetics
HAE
+$5.22M
5
LITS
Lite Strategy Inc
LITS
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 7.92%
3 Technology 1.93%
4 Industrials 1.24%
5 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CLDX icon
26
Celldex Therapeutics
CLDX
$3.24B
$4.87M 1.34%
126,000
-59,000
-32% -$2.57M
OCUL icon
27
Ocular Therapeutix
OCUL
$1.87B
$4.84M 1.34%
695,000
+139,000
+25% +$1.08M
ADMA icon
28
ADMA Biologics
ADMA
$2.33B
$4.65M 1.28%
+3,300,000
New +$4.34M
RLMD icon
29
Relmada Therapeutics
RLMD
$573M
$4.64M 1.28%
+206,000
New +$4.58M
VSTM icon
30
Verastem
VSTM
$522M
$4.62M 1.27%
187,750
– –
ACET icon
31
Adicet Bio
ACET
$75.7M
$4.6M 1.27%
16,438
+7,545
+85% +$1.29M
TVTX icon
32
Travere Therapeutics
TVTX
$5.98B
$4.38M 1.21%
141,000
– –
KLR
33
DELISTED
Kaleyra, Inc.
KLR
$4.36M 1.2%
123,969
-14,486
-10% -$551K
GMED icon
34
Globus Medical
GMED
$10.7B
$4.26M 1.17%
59,000
+20,500
+53% +$1.49M
CRIS icon
35
Curis
CRIS
$8.38M
$3.95M 1.09%
2,073
– –
EUCR
36
DELISTED
Eucrates Biomedical Acquisition Corp. Ordinary Shares
EUCR
$3.9M 1.08%
400,000
– –
SYRS
37
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3.78M 1.04%
116,000
-11,241
-9% -$455K
GKOS icon
38
Glaukos
GKOS
$10B
$3.6M 0.99%
+81,000
New +$3.74M
AVDL
39
DELISTED
Avadel Pharmaceuticals
AVDL
$3.56M 0.98%
440,589
– –
XTNT icon
40
Xtant Medical Holdings
XTNT
$60.3M
$3.5M 0.96%
6,246,291
-8,167
-0.1% -$7.7K
EXAS
41
DELISTED
Exact Sciences
EXAS
$3.42M 0.94%
+44,000
New +$3.88M
NVRO
42
DELISTED
NEVRO CORP.
NVRO
$3.4M 0.94%
42,000
-9,000
-18% -$902K
PROF
43
Profound Medical
PROF
$284M
$3.37M 0.93%
300,000
+65,000
+28% +$812K
PRDS
44
DELISTED
Pardes Biosciences, Inc. Common Stock
PRDS
$3.27M 0.9%
200,000
– –
NTRA icon
45
Natera
NTRA
$38.2B
$3.27M 0.9%
35,000
-10,500
-23% -$1.09M
SIEN
46
DELISTED
Sientra, Inc.
SIEN
$3.18M 0.88%
+86,600
New +$4.2M
CERS icon
47
Cerus
CERS
$457M
$3.17M 0.87%
465,000
-635,000
-58% -$4.27M
IMUX icon
48
Immunic
IMUX
$198M
$3.03M 0.84%
+31,700
New +$2.85M
RCOR
49
DELISTED
Renovacor, Inc.
RCOR
$2.99M 0.83%
388,845
– –
KRMD icon
50
KORU Medical Systems
KRMD
$158M
$2.99M 0.82%
995,500
+41,445
+4% +$127K
1
2
3 4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
LSA
Liberty Street Advisors New York $41.4M AUM 34.47% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return

Altium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Altium Capital Management held 173 positions worth $363M, down 4.9% from $381M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Altium Capital Management's Q4 2021 filing shows 49 new, 12 increased, 23 reduced and 40 closed positions. Its largest new stake was Esperion Therapeutics: 2,515,785 shares worth $12.6M. The largest sale was Aldeyra Therapeutics, an estimated $7.59M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Technology.

  • Altium Capital Management's largest Q4 2021 buy was Esperion Therapeutics: 2,515,785 shares worth $12.6M.
  • Altium Capital Management added most to Bicycle Therapeutics in Q4 2021, an estimated $4.41M increase.
  • Altium Capital Management's biggest Q4 2021 reduction was Cerus, cutting an estimated $4.27M.
  • Altium Capital Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $7.59M.
  • Altium Capital Management's ten largest holdings make up 26% of its $363M portfolio in Q4 2021.
  • Altium Capital Management opened 49 new positions and closed 40 in Q4 2021.
  • Altium Capital Management's portfolio value fell 4.9% quarter-over-quarter to $363M.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.